EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review

Xiulin Xiao, Wengen Zhu iD, Qixin Dai

Clinical and Applied Thrombosis/Hemostasis · 2024-01 · 30

DOI: 10.1177/10760296241303758 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 26.11.2024. Verfasst von Xiulin Xiao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Surgery, Ganzhou People's Hospital, Ganzhou, Jiangxi, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Anticoagulants, Venous Thrombosis, Portal Vein. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This systematic review aimed to evaluate the comparative effectiveness and safety of direct oral anticoagulants (DOACs) compared to traditional anticoagulation (vitamin K antagonists or low-molecular-weight heparins) in cirrhotic patients with portal vein thrombosis (PVT).

Methods

We conducted a literature search in PubMed and Embase databases up to May 2024. Studies were selected according to the PICOS criteria, focusing on cirrhotic patients with PVT treated with DOACs (dabigatran, rivaroxaban, apixaban, or edoxaban) compared to traditional anticoagulation.

Results

Our systematic review included four observational studies conducted in Japan, China, and the United States, involving a total of 223 patients with cirrhosis and PVT. The included studies collectively suggested that anticoagulation therapy, including DOACs, was associated with improved recanalization rates and reduced progression of PVT in patients with liver cirrhosis, without a significant increase in bleeding complications. Specifically, edoxaban demonstrated superior effectiveness in reducing PVT volume compared to traditional anticoagulation, while maintaining a favorable safety profile.

Conclusion

DOACs may provide a promising therapeutic option for PVT in cirrhotic patients. Further research is needed to confirm the potential benefits and risks of DOACs in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisAnticoagulantsVenous ThrombosisPortal VeinHumansAdministration, Oral

Stichwörter der Autor:innen

cirrhosisdirect oral anticoagulantslow-Molecular-Weight heparinsportal vein thrombosisvitamin k antagonists

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Hepatopancreatobiliary Surgery, Ganzhou People's Hospital, Ganzhou, Jiangxi, China.
  • Department of Cardiology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

ORCID-Profile: Wengen Zhu

Zitieren

APA

Xiao, X., Zhu, W., & Dai, Q. (2024). Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review. Clinical and Applied Thrombosis/Hemostasis, 30. https://doi.org/10.1177/10760296241303758

Vancouver

Xiao X, Zhu W, Dai Q. Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review. Clinical and Applied Thrombosis/Hemostasis. 2024;30. doi:10.1177/10760296241303758

BibTeX
@article{Xiao2024,
  author = {Xiao, Xiulin and Zhu, Wengen and Dai, Qixin},
  title = {Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2024},
  volume = {30},
  doi = {10.1177/10760296241303758}
}
Kostenlos starten →